Silver Book Fact

A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.

Parkinson Study Group. A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations. Arch Neurol. 2005; 62(2): 241-8. http://archneur.ama-assn.org/cgi/content/full/62/2/241

Reference

Title
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Publication
Arch Neurol
Publication Date
2005
Authors
Parkinson Study Group
Volume & Issue
Volume 62, Issue 2
Pages
241-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Average Annual Direct Medical Costs Per Person with Parkinson’s Disease
     
  • A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.  
  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.  
  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…  
  • Deep brain stimulation, an electrical signal delivered deep inside the brain, provides significant symptomatic relief for Parkinson’s patients whose medication is no longer effective.